BO-002

BO-002 is a preclinical-stage ophthalmic drug candidate being developed by Biophtha for the treatment of macular edema. It utilizes the company's proprietary thiomer biopolymer drug delivery platform, which consists of a non-invasive, self-administered topical hydrogel insert. This insert is designed to be placed on the ocular surface, where it provides controlled and sustained release of an undisclosed active pharmaceutical ingredient (API) for approximately seven days. The technology aims to improve therapeutic outcomes and patient compliance by reducing the burden of frequent eye drops or the need for invasive intravitreal injections commonly used to treat retinal conditions.